Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

@article{Bocchia2005EffectOA,
  title={Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial},
  author={M. Bocchia and S. Gentili and E. Abruzzese and A. Fanelli and F. Lauria},
  journal={The Lancet},
  year={2005},
  volume={365},
  pages={657-662}
}
  • M. Bocchia, S. Gentili, +2 authors F. Lauria
  • Published 2005
  • Medicine
  • The Lancet
  • BACKGROUND Although imatinib is the standard treatment for chronic myeloid leukaemia, not all patients reach complete cytogenetic remission (CCR) and most maintain detectable disease at the molecular level. We investigated whether a vaccine targeting the BCR-ABL-derived p210 fusion protein was an active and specific immunotherapy. METHODS We recruited 16 patients who had chronic myeloid leukaemia (with the b3a2 fusion point of p210), stable residual disease, a minimum treatment of 12 months… CONTINUE READING
    235 Citations

    Paper Mentions

    Interventional Clinical Trial
    This is an extension of our ongoing clinical trial using ex vivo expanded autologous Cytokine-induced killer (CIK) cells as an adoptive cellular immunotherapy for haematological… Expand
    ConditionsChronic Myeloid Leukemia
    InterventionBiological
    K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
    • 87
    • PDF
    Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination
    • 25
    WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE
    • 27
    • Highly Influenced
    • PDF
    Emerging drugs in chronic myelogenous leukaemia
    • 10
    Vaccination with autologous non‐irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia
    • 38
    Immunotherapy of myeloid leukaemia
    • 15

    References

    SHOWING 1-10 OF 33 REFERENCES
    Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
    • 1,988
    Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
    • F. Belli, A. Testori, +26 authors G. Parmiani
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2002
    • 381